Publication
Preclinical Evaluation of Labetalol for Cutaneous Melanoma Drug Repurposing: Cytotoxic Activity in A375 Cells and Mitochondria-Associated Apoptotic Signaling.
Richard Dahma, Elena-Alina Moacă, Iasmina-Alexandra Predescu, Ana-Cristiane Dragomir, Oana-Andrada Iftode, Stela Iurciuc, Diana Haj Ali, Ioana Macaşoi, Maria Sala-Cîrtog, Iulia-Najette Crintea, Alina-Doina Tănase, Marilena Dinuţi
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Background and Objectives: Drug repurposing provides an opportunity to identify anticancer activities among established pharmacological agents. Labetalol (LB), an α1- and non-selective β-adrenergic receptor antagonist, has been insufficiently investigated in melanoma. This study evaluated the…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerCutaneous Melanomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available